Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response.
It has previously been shown that sera from multiparous women have increased levels of anti-idiotypic antibodies specific for anti-HLA molecules. gamma-Globulins prepared from these sera may be superior to commercial preparations of intravenous gamma-globulin (IVIg) for inhibiting HLA alloimmunization. To test this, F(ab')2 fragments prepared from either commercial IVIg or from the sera of men or multiparous women were coupled to CNBr-Sepharose and tested for their ability to bind F(ab')2 fragments derived from polyspecific anti-HLA sera. As determined by flow cytometry, compared with columns coated with F(ab')2 derived from commercial IVIg or sera from men, columns coated with F(ab')2 prepared from the sera of multiparous women bound significantly more anti-HLA. In addition, intact IgG molecules prepared from the sera of multiparous women significantly neutralized the reactivity of the anti-HLA F(ab')2 fragments. To determine whether the intact IgG molecules or their corresponding F(ab')2 fragments could affect in vivo alloimmunity, they were tested for their ability to inhibit an established IgG human alloimmune response in humanized severe combined immunodeficient (SCID) mice. Compared with commercial IVIg, when intact IgG or F(ab')2 fragments derived from multiparous women were administered to SCID mice making human anti-HLA antibodies, a significant reduction in anti-HLA reactivity was observed. The findings suggest that IgG molecules prepared from the sera of multiparous women have increased anti-idiotypic reactivity against anti-HLA antibodies, which can significantly inhibit an established human IgG alloimmune response in an Fc-independent manner.
Department of Laboratory Medicine and Pathobiology, St Michael's Hospital, Toronto, Ontario, Canada. semplej@smh.toronto.ca
John W
JW
Semple
Michael
M
Kim
Alan H
AH
Lazarus
John
J
Freedman
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000097:blood* / Q000235:genetics / Q000276:immunology; D002846:Chromatography, Affinity; D004341:Drug Evaluation; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood / Q000235:genetics / Q000276:immunology; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D010298:Parity / Q000276:immunology*; D011485:Protein Binding; D005719:gamma-Globulins / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D006680:HLA Antigens; D007140:Immunoglobulin Fab Fragments; D016756:Immunoglobulins, Intravenous; D007518:Isoantibodies; D005719:gamma-Globulins